Target Name: MIR936
NCBI ID: G100126326
Review Report on MIR936 Target / Biomarker Content of Review Report on MIR936 Target / Biomarker
Other Name(s): MicroRNA 936 | microRNA 936 | hsa-mir-936 | MIRN936 | hsa-miR-936

MIR936: The Emerging Biomarker and Drug Target

In recent years, the study of non-coding RNAs has gained significant attention due to their involvement in various cellular processes, including gene regulation and disease progression. One such non-coding RNA, MIR936, has emerged as a potential biomarker and drug target with immense diagnostic and therapeutic implications. This article aims to explore the role of MIR936 in human health and disease, highlighting its significance as a biomarker and potential target for drug development.

What is MIR936?
MIR936, also known as microRNA-936, is a small non-coding RNA molecule that is transcribed from the genome but does not encode proteins. MicroRNAs (miRNAs) are well-defined regulatory molecules that modulate gene expression post-transcriptionally. MIR936 is found in various human tissues, with differential expression patterns in different cell types. Studies have indicated its involvement in multiple cellular processes, including cell proliferation, differentiation, and apoptosis.

MIR936 as a Biomarker:
In recent years, researchers have identified numerous miRNAs as potential biomarkers for various diseases, including cancer, cardiovascular disorders, and neurodegenerative diseases. MIR936, in particular, has shown promise as a non-invasive diagnostic tool due to its stable presence in bodily fluids, including blood, urine, and saliva. Altered expression patterns of MIR936 have been observed in several diseases, making it a potential biomarker for disease diagnosis, prognosis, and monitoring.

1. Cancer Biomarker:
Cancer is a leading cause of mortality worldwide, necessitating the development of reliable biomarkers for early detection and effective treatment. MIR936 has been implicated in various forms of cancer, including breast, lung, colorectal, and ovarian cancer. Studies have demonstrated its diagnostic potential as aberrant expression levels of MIR936 are detected in cancer tissues and bodily fluids of cancer patients. Furthermore, MIR936 has shown prognostic value, with its expression correlating with tumor grade, metastasis, and patient survival rates.

2. Cardiovascular Biomarker:
Cardiovascular diseases (CVDs) pose a significant health burden globally, necessitating the identification of biomarkers for risk assessment and therapeutic intervention. MIR936 has emerged as a potential biomarker for CVDs, with altered expression levels detected in serum samples of patients with heart failure, coronary artery disease, and myocardial infarction. Its upregulation in these conditions suggests its potential as a diagnostic marker for CVDs and a predictor of disease severity.

3. Neurodegenerative Biomarker:
Neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, are characterized by progressive neuronal loss and cognitive decline. Early detection and intervention are crucial for improving patient outcomes. MIR936 has shown promise as a biomarker for neurodegenerative diseases, with studies indicating its altered expression levels in the cerebrospinal fluid and brain tissues of affected individuals. While more research is needed, MIR936 holds potential as a diagnostic and prognostic biomarker in these debilitating conditions.

MIR936 as a Drug Target:
In addition to its diagnostic potential, MIR936 has also garnered attention as a potential target for therapeutic intervention. Drug discovery efforts have focused on developing miRNA-based treatments that modulate the expression of disease-associated miRNAs such as MIR936. Several strategies are being explored, including the use of antisense oligonucleotides, small molecule inhibitors, and the delivery of synthetic miRNA mimics or inhibitors.

1. Cancer Therapeutics:
The dysregulated expression of MIR936 in various cancer types highlights its potential as a therapeutic target. Researchers are exploring the development of miRNA-based therapeutics that restore or inhibit the expression of MIR936, thereby affecting downstream gene expression associated with tumor growth and metastasis. Preclinical studies utilizing miRNA mimics or inhibitors have shown promising results, inhibiting tumor growth and sensitizing cancer cells to chemotherapy.

2. Cardiovascular Interventions:
MIR936's involvement in cardiovascular diseases opens up new avenues for therapeutic interventions. Targeted suppression or restoration of MIR936 expression may modulate pathways involved in endothelial dysfunction, atherosclerosis, and cardiac remodeling. By normalizing MIR936 expression levels, it may be possible to slow disease progression and improve cardiovascular outcomes.

3. Neuroprotective Strategies:
Given the potential role of MIR936 in neurodegenerative diseases, strategies targeting this miRNA hold promise in preserving neuronal function and preventing disease progression. Modulation of MIR936 expression may regulate key molecular pathways implicated in neurodegeneration, offering novel therapeutic possibilities for these devastating disorders.

MIR936, a non-coding RNA molecule, has emerged as an important biomarker and potential target for therapeutic interventions in various diseases. Its differential expression patterns in different diseases makes it a valuable diagnostic tool, while its involvement in vital cellular processes positions it as a potential target for drug development. The continued exploration of MIR936's roles and functions will undoubtedly pave the way for breakthroughs in disease diagnosis, treatment, and the ultimate improvement of patient outcomes.

Protein Name: MicroRNA 936

The "MIR936 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR936 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

MIR937 | MIR938 | MIR939 | MIR940 | MIR941-1 | MIR941-2 | MIR941-3 | MIR941-4 | MIR941-5 | MIR942 | MIR943 | MIR944 | MIR95 | MIR96 | MIR98 | MIR99A | MIR99AHG | MIR99B | MIRLET7 | MIRLET7A1 | MIRLET7A2 | MIRLET7A3 | MIRLET7B | MIRLET7BHG | MIRLET7C | MIRLET7D | MIRLET7E | MIRLET7F1 | MIRLET7F2 | MIRLET7G | MIRLET7I | MIS12 | MIS12 complex | MIS18A | MIS18A-AS1 | MIS18BP1 | MISFA | MISP | MISP3 | MITD1 | MITF | Mitochondrial complex I assembly complex | Mitochondrial import inner membrane translocase 23 (TIM23) complex | Mitochondrial inner membrane protease complex | Mitochondrial membrane ATP synthase | Mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) | Mitochondrial pyruvate carrier complex (MPC) | Mitochondrial RNA processing endoribonuclease | Mitofilin Complex | Mitofusin | Mitogen-Activated Protein Kinase | Mitogen-activated protein kinase (JNK) | Mitogen-Activated Protein Kinase (MAP Kinase)-Activated Protein Kinase | Mitogen-Activated Protein Kinase Kinase Kinase (MAP3K) | Mitogen-activated protein kinase p38 (MAPK p38) | MITRAC complex | MIX23 | MIXL1 | MKI67 | MKKS | MKLN1 | MKLN1-AS | MKNK1 | MKNK1-AS1 | MKNK2 | MKRN1 | MKRN2 | MKRN2OS | MKRN3 | MKRN4P | MKRN7P | MKRN9P | MKS1 | MKX | MLANA | MLC1 | MLEC | MLF1 | MLF1-DT | MLF2 | MLH1 | MLH3 | MLIP | MLIP-AS1 | MLKL | MLLT1 | MLLT10 | MLLT10P1 | MLLT11 | MLLT3 | MLLT6 | MLN | MLNR | MLPH | MLST8 | MLX | MLXIP | MLXIPL | MLYCD | MMAA